HCC - HEPATOCELLULAR CARCINOMA
Clinical trials for HCC - HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HCC - HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HCC - HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo aims to stop liver cancer return after surgery
Disease control OngoingThis phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Universal CAR-T therapy targets Hard-to-Treat liver and lung cancers
Disease control TerminatedThis early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy combo may boost liver cancer ablation outcomes
Disease control OngoingThis phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer cocktail aims to rev up immune system against tumors
Disease control OngoingThis early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo therapy shows promise for untreatable liver cancer
Disease control OngoingThis study looks at whether a three-part treatment—blocking the tumor's blood supply (TACE), precise radiation (SBRT), and drugs that boost the immune system—can help people with intermediate to advanced liver cancer that cannot be removed by surgery. The 17 participants all rece…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: NA • Sponsor: Université de Montréal • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
AI tool aims to predict where liver cancer spreads next
Knowledge-focused OngoingThis study is testing a machine learning tool that predicts the risk of liver cancer spreading to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread are being followed to see if the tool helps doctors make better decisions about monitoring. The tool gi…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC